You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 19, 2024

CLINICAL TRIALS PROFILE FOR BREXUCABTAGENE AUTOLEUCEL


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for brexucabtagene autoleucel

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02601313 ↗ Study to Evaluate the Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma Active, not recruiting Kite, A Gilead Company Phase 2 2015-11-09 The primary objective of the study is to evaluate the efficacy of brexucabtagene autoleucel (KTE-X19) in participants with relapsed/refractory mantle cell lymphoma (MCL)
NCT02614066 ↗ A Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3) Active, not recruiting Kite, A Gilead Company Phase 1/Phase 2 2016-03-07 The primary objectives of this study are to determine the safety and efficacy of brexucabtagene autoleucel (KTE-X19) adult participants with relapsed/refractory (r/r) B-precursor acute lymphoblastic leukemia (ALL).
NCT02625480 ↗ Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Recruiting Kite, A Gilead Company Phase 1/Phase 2 2016-02-01 The primary objectives of this study are to evaluate the safety and efficacy of brexucabtagene autoleucel (KTE-X19) in pediatric and adolescent participants with relapsed/refractory (r/r) B-precursor acute lymphoblastic leukemia (ALL) or relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (NHL).
NCT03624036 ↗ Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Active, not recruiting Kite, A Gilead Company Phase 1 2018-11-15 The primary objective of this study is to evaluate the safety and tolerability of brexucabtagene autoleucel (KTE-X19) in adults with relapsed/refractory chronic lymphocytic leukemia (r/r CLL) and small lymphocytic lymphoma (r/r SLL).
NCT03642626 ↗ MT2017-45: CAR-T Cell Therapy for Heme Malignancies Recruiting Masonic Cancer Center, University of Minnesota 2018-12-18 This is a phase II study of FDA-approved CAR-T products for patients with hematologic malignancies. Patients will be assigned to Arm A and B based on age and diagnosis. Overall remission rate, safety events and other endpoints will be calculated for Arm A and B separately.
NCT04880434 ↗ Study to Evaluate the Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) Recruiting Kite, A Gilead Company Phase 2 2021-04-27 The primary objective is to evaluate the efficacy of brexucabtagene autoleucel (KTE-X19) in participants with relapsed/refractory (r/r) mantle cell lymphoma (MCL) in Cohort 3 of this study.
NCT05495464 ↗ A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma Not yet recruiting Acerta Pharma, LLC Early Phase 1 2023-01-31 To learn if giving acalabrutinib, rituximab, and brexucabtagene autoleucel to patients with previously untreated high-risk mantle cell lymphoma (MCL) can help to control the disease.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for brexucabtagene autoleucel

Condition Name

Condition Name for brexucabtagene autoleucel
Intervention Trials
Relapsed/Refractory Mantle Cell Lymphoma 2
Acute Lymphoblastic Leukemia 2
Relapsed/Refractory Chronic Lymphocytic Leukemia 1
Relapsed/Refractory Chronic Lymphocytic Leukemia and Relapsed/Refractory Small Lymphocytic Lymphoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for brexucabtagene autoleucel
Intervention Trials
Lymphoma 5
Leukemia, Lymphoid 4
Precursor Cell Lymphoblastic Leukemia-Lymphoma 3
Leukemia 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for brexucabtagene autoleucel

Trials by Country

Trials by Country for brexucabtagene autoleucel
Location Trials
United States 76
Netherlands 4
Germany 4
France 4
Canada 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for brexucabtagene autoleucel
Location Trials
Texas 6
New York 5
Florida 5
California 5
Tennessee 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for brexucabtagene autoleucel

Clinical Trial Phase

Clinical Trial Phase for brexucabtagene autoleucel
Clinical Trial Phase Trials
Phase 2 3
Phase 1/Phase 2 2
Phase 1 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for brexucabtagene autoleucel
Clinical Trial Phase Trials
Recruiting 3
Active, not recruiting 3
Not yet recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for brexucabtagene autoleucel

Sponsor Name

Sponsor Name for brexucabtagene autoleucel
Sponsor Trials
Kite, A Gilead Company 7
Masonic Cancer Center, University of Minnesota 1
Acerta Pharma, LLC 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for brexucabtagene autoleucel
Sponsor Trials
Industry 7
Other 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.